Influence of Parenteral Iron Therapy and Oral Vitamin E Supplementation on Neutrophil Respiratory Burst in Chronic Hemodialysis Patients

Renal Failure ◽  
2005 ◽  
Vol 27 (2) ◽  
pp. 135-141 ◽  
Author(s):  
Magdalena Hodkova ◽  
Sylvie Dusilova-Sulkova ◽  
Anna Skalicka ◽  
Marta Kalousova ◽  
Tomas Zima ◽  
...  
Keyword(s):  
Vitamin E ◽  
Respiratory Burst ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Iron Therapy ◽  
Oral Vitamin ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy ◽  
Neutrophil Respiratory Burst ◽  
Vitamin E Supplementation

scholarly journals Hemosiderosis secondary to parenteral iron therapy in chronic hemodialysis patients

1983 ◽  
Vol 16 (1) ◽  
pp. 49-54
Author(s):  
Kazuo Fukuda ◽  
Takao Saito ◽  
Toshio Kyogoku ◽  
Kei Yamakage ◽  
Hiroshi Sato ◽  
...  
Keyword(s):  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Iron Therapy ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy

Vitamin E Supplementation Increases LDL Resistance to ex vivo Oxidation in Hemodialysis Patients

2003 ◽  
Vol 73 (4) ◽  
pp. 290-296 ◽  
Author(s):  
Badiou ◽  
Cristol ◽  
Morena ◽  
Bosc ◽  
Carbonneau ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Vitamin E ◽  
High Performance ◽  
Ex Vivo ◽  
Density Lipoprotein ◽  
Thiobarbituric Acid ◽  
Hemodialysis Patients ◽  
Ldl Oxidation ◽  
Oral Vitamin ◽  
Vitamin E Supplementation

Background: Oxidative stress and alterations in lipid metabolism observed in hemodialysis patients potentiate the low-density lipoprotein (LDL) oxidability, recognized as a key event during early atherogenesis. Objective: To explore the effects of an oral vitamin E supplementation on oxidative stress markers and LDL oxidability in hemodialysis patients. Methods: Fourteen hemodialysis patients and six healthy volunteers were given oral vitamin E (500 mg/day) for six months. Oxidative stress was assessed using: plasma and lipoprotein vitamin E levels [high-performance liquid chromatography (HPLC) procedure]; thiobarbituric acid reactive substances (TBARS, Yaggi method); and copper-induced LDL oxidation. All parameters were evaluated before initiation of vitamin E supplementation, and at three and six months thereafter. Results: At baseline, a significantly higher TBARS concentration and a higher LDL oxidability were observed in hemodialysis patients when compared to controls. After six months of vitamin E supplementation, TBARS and LDL oxidability were normalized in hemodialysis patients. Conclusion: Our data confirm that hemodialysis patients are exposed to oxidative stress and increased susceptibility to ex vivo LDL oxidation. Since oral vitamin E supplementation prevents oxidative stress and significantly increases LDL resistance to ex vivo oxidation, supplementation by natural antioxidants such as vitamin E may be beneficial in hemodialysis patients.

scholarly journals Influence of Oral Vitamin E Therapy on Micro-Inflammation and Cardiovascular Disease Markers in Chronic Hemodialysis Patients

Renal Failure ◽  
2006 ◽  
Vol 28 (5) ◽  
pp. 395-399 ◽  
Author(s):  
Magdalena Hodkova ◽  
Sylvie Dusilova-Sulkova ◽  
Marta Kalousova ◽  
Jirina Soukupova ◽  
Tomas Zima ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Vitamin E ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Oral Vitamin ◽  
Disease Markers

Parenteral Iron Therapy: A Single Institution's Experience Over a 5-Year Period

2005 ◽  
Vol 3 (6) ◽  
pp. 791-795 ◽  
Author(s):  
Christopher A. Laman ◽  
Scott B. Silverstein ◽  
George M. Rodgers
Keyword(s):  
Adverse Event ◽  
Adverse Events ◽  
Iron Sucrose ◽  
Iron Therapy ◽  
Iron Dextran ◽  
Serious Adverse Events ◽  
Exact Test ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy ◽  
Event Rates

Many patients require parenteral iron therapy for optimal correction of anemia, including cancer patients who require erythropoietic drugs. Available parenteral iron therapy options include iron dextran, iron gluconate, and iron sucrose. The purpose of this study is to summarize our institution's experience with parenteral iron therapy over a 5-year period, with a focus on comparative safety profiles. All patients receiving parenteral iron therapy over this period were included in the analysis. Chi-squared test and Fisher's exact test were used to compare the adverse event rates of each product. A total of 121 patients received 444 infusions of parenteral iron over this period. Iron dextran was the most commonly used product (85 patients) and iron sucrose was the least used (2 patients). Iron gluconate was used by 34 patients. Overall adverse event rates per patient with iron dextran and iron gluconate were 16.5% and 5.8%, respectively (P = .024). Premedication with diphenhydramine and acetaminophen before infusions of iron dextran reduced adverse event rates per infusion from 12.3% to 4.4% (P = .054). Test doses of iron dextran were used 88% of the time for initial infusions of iron dextran. All adverse events for all parenteral iron products were mild or moderate. There were no serious adverse events and no anaphylaxis was observed. Our results suggest that, if test doses and premedications are used, iron dextran is an acceptable product to treat iron deficiency.

Sign in / Sign up

Export Citation Format

Share Document